8-K: OpGen Sells Unyvero Assets and Customer Contracts to Camtech Amid Strategic Shift

OpGen, Inc. has agreed to sell its Unyvero customer contracts and installed base to Camtech Pte Ltd for $218,000, marking a significant step in its strategic shift.

Summary

• OpGen has entered into an agreement with Camtech Pte Ltd to sell its Unyvero customer contracts and installed base for $218,000.
• This transaction follows Camtech's prior acquisition of assets from OpGen's subsidiary, Curetis GmbH, during its insolvency proceedings.
• OpGen has also offered Camtech the option to purchase remaining Unyvero inventory for up to an additional $176,000.
• Until the remaining inventory is sold, OpGen will continue to provide commercial operations and service support for the Unyvero systems.
• These transactions are part of OpGen's plan to exit the Unyvero business and explore strategic alternatives, including a potential reverse merger.
• OpGen's subsidiary, Ares Genetics GmbH, also sold its assets, including the ARESdb database, to bioMerieux S.A. as part of its insolvency proceedings.

Sentiment

Score: 3

Explanation: The document indicates a significant strategic shift due to financial difficulties, including the insolvency of subsidiaries and the sale of assets at a low price. While the company is attempting to reposition itself, the overall tone suggests a challenging situation.

Positives

• The sale of Unyvero assets provides OpGen with immediate cash of $218,000.
• The potential sale of remaining inventory could bring in an additional $176,000.
• The transactions align with OpGen's strategy to explore strategic alternatives, including a potential reverse merger.
• OpGen is exiting a business line that was likely a financial burden.

Negatives

• OpGen is exiting its Unyvero business, indicating a potential lack of profitability or strategic fit.
• The sale of Curetis and Ares Genetics assets occurred as part of insolvency proceedings, suggesting financial difficulties within those subsidiaries.
• OpGen did not participate in the sale of its subsidiaries' assets, indicating a lack of control over the process.
• The sale price of $218,000 for the customer contracts and installed base seems low.

Risks

• The transactions may not be completed as expected.
• OpGen's ability to find a suitable strategic alternative, such as a reverse merger, is not guaranteed.
• The company faces risks related to its ability to regain compliance with Nasdaq listing rules.
• OpGen's ability to finance its business and operations is uncertain.
• The company's liquidity and working capital requirements may pose challenges.

Future Outlook

OpGen is focusing on strategic alternatives, including a potential reverse merger, and is exiting the Unyvero business. The company is working to transition its U.S. Unyvero customers and business to Camtech.

Management Comments

• David Lazar, Chairman and CEO of OpGen, stated that these transactions are consistent with the company's strategy of preparing for a potential strategic transaction, including a potential reverse merger.
• He believes a strategic transaction would be an attractive proposition to OpGen stockholders who could benefit from future value growth.

Industry Context

The sale of OpGen's Unyvero assets and the insolvency of its subsidiaries suggest challenges in the molecular diagnostics market. The company is shifting its focus, possibly due to competitive pressures or financial difficulties in its current business model.

Comparison to Industry Standards

• The sale of assets due to insolvency proceedings is not uncommon in the biotech industry, particularly for companies struggling to achieve profitability.
• The sale of assets to a family office like Camtech is less common than sales to strategic acquirers or private equity firms.
• The low sale price of $218,000 for the customer contracts and installed base suggests that the Unyvero business was not performing well or that OpGen was in a weak negotiating position.
• The sale of Ares Genetics' assets to bioMerieux S.A. is a more typical transaction, as bioMerieux is a strategic player in the diagnostics space.

Stakeholder Impact

• Shareholders may be concerned about the company's financial situation and the sale of assets at a low price.
• Employees in the Unyvero business may be affected by the transition to Camtech.
• Customers of the Unyvero systems will be transitioned to Camtech.
• Creditors of Curetis and Ares Genetics may be impacted by the insolvency proceedings.

Next Steps

• OpGen will work with Camtech and the Curetis team to transfer and transition its U.S. Unyvero customers and business.
• OpGen will continue to maintain commercial operations and service support for the Unyvero systems until the remaining inventory is sold.
• OpGen will continue to seek strategic alternatives, including a potential reverse merger.

Key Dates

Keywords

Unyvero, Camtech, OpGen, strategic transaction, reverse merger, asset sale, insolvency, Curetis, Ares Genetics, inventory